<p>2007</p><p>COURSE #1 - STUDY DIRECTOR TRAINING – ALL DAY Chair: Barbara J. Mounho, Ph.D., DABT, Toxicologist Research Scientist, Amgen Inc., Thousand Oaks, CA</p><p>COURSE #2 - RISK ASSESSMENT: CURRENT PRACTICES AND FUTURE DIRECTIONS – ALL DAY Chair: Annette M. Shipp, Ph.D., Principal, ENVIRON International Corporation, Ruston, LA</p><p>COURSE #3 - CARDIOVASCULAR ASSESSMENT: THE PRECEDING, CONTEMPORARY AND PROSPECTIVE VIEWPOINT Co-Chairs: Alfred N. Botchway, Ph.D., President, Xenometrics, LLC, Stilwell, KS and Elaine V. Knight, Ph.D., Research Fellow, Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, NJ</p><p>COURSE #4 - RESPIRATORY DRUG DEVELOPMENT - A REVIEW OF CURRENT KNOWLEDGE Chair: Norman Kim, M.S., DABT, Inotek Pharmaceuticals Corporation, Beverly, MA</p><p>COURSE #5 - APPLICATION OF THE HUMAN RELEVANCE FRAMEWORK TO THE ANALYSIS OF RODENT TUMOR DATA Co-Chairs: Jerry F. Hardisty, DVM, DACVP, Fellow IATP, President/Veterinary Pathologist, EPL Inc., Research Triangle Park, NC and Douglas C. Wolf, DVM, Ph.D., Fellow IATP, Staff Scientist, US EPA, Environmental Carcinogenesis Division, Natl Health & Environmental Effects Research Laboratory, Research Triangle Park, NC</p><p>COURSE #6 - SCREENING FOR DRUG ABUSE POTENTIAL: GUIDELINES AND EXPECTATIONS Chair: Gene E. Schulze, Ph.D., DABT, Group Director, Dept. of Toxicology, Bristol-Myers Squibb Company, Syracuse, NY</p><p>SYMPOSIUM I - WHAT YOU ALWAYS WANTED TO KNOW ABOUT REACH; BUT WERE AFRAID TO ASK Co-Chairs: James C. Lamb, IV, Ph.D., DABT, Senior Vice President, The Weinberg Group, Washington DC and Michael Holsapple, Ph.D., ATS, Executive Director, ILSI / HESA, Washington, DC </p><p>SYMPOSIUM II - INHALATION TOXICOLOGY: TECHNOLOGICAL AND REGULATORY TIPS OF THE TRADE Co-Chairs: Hilary Sheevers, Ph.D., President, CEO, Aclairo Pharmaceutical Development Group, Inc., Vienna, VA and Theresa Sweeney, Ph.D., Director Life Sciences, Nektar Therapeutics, San Carlos, CA</p><p>SYMPOSIUM III - USE OF NON-MAMMALS FOR TOXICOLOGICAL AND DRUG DISCOVERY STUDIES Chair: Michael Ashner, Ph.D., Professor, Vanderbilt University Medical Center, Nashville, IL SYMPOSIUM IV - COMBINATION TOXICOLOGY Co-Chairs: Melissa Rhodes, Ph.D., Project Manager, Safety Assessment, GlaxoSmithKline, Research Triangle Park, NC and Michael Wyde, Ph.D., DABT, Toxicologist, NTP, Research Triangle Park, NC</p><p>SYMPOSIUM V- BUILDING COMPREHENSIVE IN VITRO SCREENING APPROACHES FOR PREDICTING ANIMAL AND HUMAN TOXICITY: IMPROVING THE DRUG SELECTION PROCESS Co-Chairs: James M. McKim, IV, Ph.D., DABT, President/CEO, CeeTox, Inc., Kalamazoo, MI and Edward LeCluyse, Ph.D., Chief Scientific Officer, CellzDirect, Pittsboro, NC</p><p>SYMPOSIUM VI - THE IMPACT OF IMMUNOTOXICITY ON MOVING PHARMACEUTICAL PRODUCTS THROUGH CLINICAL DEVELOPMENT Co-Chairs: Marque D. Todd, DVM, DABT, Principal Scientist, Amgen Inc., Thousand Oaks, CA and Barbara Mounho, Ph.D., DABT, Principal Scientist, Amgen Inc., Thousand Oaks, CA</p><p>SYMPOSIUM VII - SAFETY PHARMACOLOGY Co-Chairs: Stephen Wilson , Scientist I, Safety Sciences, Charles River Laboratories, Worcester, MA and Kenneth J. Olivier Jr., Ph.D., Project Manager/Investigative Toxicologist, GlaxoSmithKline, Research Triangle Park, NC</p><p>SYMPOSIUM VIII - PEDIATRIC INITIATIVES AND CONCERNS Co-Chairs: Mildred S. Christian, Ph.D., Fellow, ATS, President, Argus International, Inc., Horsham, PA and Alan B. Hoberman, Ph.D., Fellow, ATS, DABT, General Manager, Charles River Laboratories - PA, Horsham, PA</p><p>SYMPOSIUM IX - SMOKING AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE: STATE OF KNOWLEDGE AND FUTURE DISCUSSIONS Co-Chairs: Willie J. McKinney, Ph.D., DABT, Principal Scientist, Philip Morris USA, Richmond, VA and Chris Coggins, Ph.D., DABT, Consultant, Carson Watts Consulting, King, NC</p><p>SYMPOSIUM X - CURRENT TRENDS AND ADVANCEMENT IN ENVIRONMENTAL CHEMICAL RISK ASSESSMENT Co-Chairs: Richard Phillips, ExxonMobil Petroleum & Chemical, Machelen, Belgium and Richard A. Becker, American Chemistry Council, Arlington, VA</p><p>SYMPOSIUM XI - DERMAL ABSORPTION: AN IMPORTANT CONSIDERATION FOR RISK ASSESSMENT - MODELS AND THEIR APPLICATIONS Co-Chairs: Jon F. Lalko, B.S., Senior Program Specialist, Human Health, RIFM, Inc. Woodcliff Lake, NJ and Daniel Isola, Newburgh, NY</p><p>SYMPOSIUM XII - TOXICOLOGIC CONSIDERATIONS IN THE TREATMENT OF OBESITY Chair: Tracey Zoetis, M.S., Managing Consultant, SciLucent, LLC, Herndon, VA SYMPOSIUM XIII - STRESS AS A CONFOUNDING FACTOR IN THE CONDUCT AND INTERPRETATION OF TOXICOLOGICAL STUDIES Co-Chairs: Jerry F. Hardisty, DVM, DACVP, President, EPL, Inc., Research Triangle Park, NC and L.D. Hopper, DVM, Ph.D., DABT, Director of Toxicology, BASi, Mount Vernon, IN</p><p>SYMPOSIUM XIV - REPRODUCTIVE AND DEVELOPMENTAL RISK ASSESSMENT FOR BIOLOGICS IN THE NONHUMAN PRIMATE MODEL: WHEN AND HOW SHOULD STUDIES BE CONDUCTED? Co-Chairs: Gerhard Weinbauer, Ph.D., Director, Research and Safety Assessment, Covance Laboratories GmbH, Muenster, Germany and Barbara J. Mounho, Ph.D., DABT, Principal Scientist, Amgen Inc., Thousand Oaks, CA</p><p>SYMPOSIUM XV - EXPERIENCES WITH MICRODOSING TRIALS Co-Chairs: Melissa Rhodes, Ph.D., Project Manager, Safety Assessment, GlaxoSmithKline, Research Triangle Park, NC and Colin Garner, Bpharm, Ph.D., D.Sc., FRCPath, Founder and CEO, Xceleron Inc., Heslington, UK</p><p>SYMPOSIUM XVI - SAFETY EVALUATION OF OCULAR DRUGS FOR RETINAL DISEASES: FOCUS ON STRATEGIES AND PRACTICAL APPROACHES Co-Chairs: Brian Short, VDM, Ph.D., DACVP, Senior Director, Pathology, Allergan, Inc., Irvine, CA and Andrea Weir, Ph.D., DABT, Senior Scientific Advisor, Charles River Laboratories, Navigators, Sparks, NV</p><p>SYMPOSIUM XVII - HOT TOPICS IN DRUG DEVELOPMENT Co-Chairs: Drew Badger, Ph.D., DABT, Director, Discovery Toxicology and Scientific Operations, Allergan, Inc., Irvine, CA and Mary Ellen Cosenza, Ph.D., DABT, RAC, Executive Director, Regulatory Affairs, Amgen Inc., Thousand Oaks, CA</p><p>SYMPOSIUM XVIII - CONDUCTING NONCLINICAL TOXICOLOGY STUDIES IN CHINA: OPPORTUNITIES, ISSUES, AND CONCERNS Co-Chairs: Vincent L. Reynolds, Ph.D., DABT, Principal Research Toxicologist, Eli Lilly and Company, Greenfield, IN and William Chen, Ph.D., DABT, Professor, China Agricultural University, Beijing, PRC</p>